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1. Introduction 
Novel immunosuppressants have decreased the incidence rate of acute rejection 
significantly, but fail to prevent chronic allograft dysfunction (CAD). Around 40% patients 
develop CAD gradually in several months or several years after renal transplantation. They 
present with progressive deterioration of long-term allograft function and allograft failure, 
and end up with resuming dialysis. It has also been demonstrated that CAD may increase 
the cardiovascular mortality after renal transplantation. Therefore, it is crucial for promoting 
long-term allograft survival to investigate the pathogenesis and preventive and therapeutic 
strategies of CAD. CAD, formerly termed chronic rejection (CR), is also known as late graft 
loss (LGI) or chronic allograft nephropathy (CAN), since it involves both immune factors 
(transplantation antigen dependent) and non-immune factors (transplantation antigen 
independent).  
CAD refers to progressive functional impairment of allograft, with pathologic changes 
including tubular atrophy, interstitial fibrosis, progressive glomerulosclerosis, and arterial 
fibrous intimal thickening and arteriole hyalinosis. These pathologic changes include 
immune and non-immune injury to allograft. Chronic rejection is usually associated with 
acute rejection or subclinical rejection, HLA mismatch, panel reactive antibodies (PRA), and 
donor specific antibodies (DSA). In contrast, non-immune allograft injury is usually 
associated with calcineurin inhibitors (CNI), preexisting delayed graft function (DGF), 
hypertension, hyperlipidemia, proteinuria, viral infection, chronic obstruction and chronic 
pyelonephritis. In addition, CAD includes recurrent kidney disease, de novo nephritis, 
posttransplantation lymphoproliferative diseases (PTLD). Many of the above-mentioned 
factors that lead to CAD usually exist simultaneously; thus, the pathologic manifestations of 
CAD are complex and not specific, making the treatment of CAD difficult. In short, there are 
many factors influencing the incidence and development of CAD, and the pathogenesis of 
CAD remains largely unclear. Microcirculation injury mediated by donor specific antibodies 
is thought to be the major cause for long-term allograft dysfunction.  
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2. Risk factors for CAD  
2.1 Transplantation antigen dependent risk factors  
Epidemiologic study indicated that patients with acute rejection are more likely to develop 
chronic rejection than those without. The frequency, histologic type and time of onset of 
acute rejection are closely associated with allograft dysfunction. In particular, frequent and 
delayed (more than one year) acute rejection is likely to result in allograft dysfunction. 
Gulanikar et al. reported that the risk for CAD was 9% in patients developing acute rejection 
once after renal transplantation, was 38% in those developing acute rejection twice, and was 
50% in those developing acute rejection thrice, and that early-stage acute vascular rejection 
was more harmful than acute interstitial rejection. Van et al. reported that the the 5-year 
kidney survival rates were 34%, 71%, and 74% in patients developing acute vascular 
rejection, acute interstitial rejection, and without acute rejection in the 3 months after 
transplantation. It was reported that acute rejection may increase the expression of platelet-
derived growth factor (PDGF) and its receptor on arterial smooth muscle cells. PDGF is one 
of the main stimulators for interstitial cell proliferation in CAD. Hence, PDGF may play a 
role in acute rejection and CAD.  
1. HLA match    
Major Histocompability Complex (MHC) mismatch is a crucial risk factor for CAD. The 
long-term allograft survival rate is the highest for cadaveric renal transplantation with 
perfect MHC match, and CAD does not occur following homogenic transplantation. Among 
HLA-A, B, and DR, group A is not so important as groups B and D. Mismatch of both loci of 
group B is likely to lead to acute rejection and subsequent chronic rejection. In the presence 
of mismatch of one locus of group B and one locus of group DR, 82% of type I helper T cells 
proliferate; in the absence of mismatch, only 6% proliferate. Meanwhile, in the presence of 
mismatch, the release of allogenic antigen peptide increases by 10 folds. The long-term 
allograft survival rates differ significantly with different number of mismatching MHC sites, 
suggesting the importance of transplantation antigen dependent factors in the development 
of CAD.  
2. Antibodies  
The main mechanism for CAD is believed to relate to allograft stimulated production of 
anti-donor specific circulating antibodies. As currently available immunosuppressants 
mainly suppress T cells, antibodies might be a main factor for chronic rejection. In chronic 
allograft rejection, there are many antibody-secreting plasma cells in the kidney, and these 
antibodies are against mesenterial cells, focal adhesion plaques, molecules synthesized and 
secreted by activated mesenterial cells or basement membrane antigen. Interfering 
recombination activation gene 2(RAG-2) will lead to T and B cell defect, and immunoglobin 
transmembrane domain-encoding gene defect will preclude the production of mature B cells 
and antibodies. In both cases, allograft atherosclerosis will not occur. In addition, 
macrophage dysfunction and defect of MHC class II antigen mitigate atherosclerosis, and 
defects of MHC class I antigen, CD8 positive cells and NK cells exacerbate atherosclerosis.  
Hypersensitivity to panel reactive antibodies (PRA) correlates highly to acute rejection. PRA 
or the reaction rate of donor lymphocytes to recipient serum is frequently used to predict 
the risk for acute rejection. Preoperative PRA being more than 10% correlates significantly to 
the three-year allograft survival rate. Anti-lymphocyte antibody was detected in 28.2% 
patients with chronic rejection, and of them, 57% were found to have anti-HLA antibody. In 
vitro study confirmed that monoclonal antibody against type I HLA molecule induced the 
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expression of fibroblast growth factors receptor on endothelial cells and smooth muscle 
cells. Allogenic antibodies exhibit the same effect, and they promote glomerulosclerosis and 
fibrosis. Antibodies against occult epitopes may cause chronic damage, and elevated levels 
of antibodies against molecules contributing to tissue injury will lead to excessive fibrosis 
during tissue repair.  
3. TGF-ǃ1 pathway  
It was demonstrated that molecules recognized by antibodies following transplantation, 
biglycans and modified molecules also bind to TGF-ǃ1. TGF-ǃ1 is the main cytokine 
regulating CAD fibrosis. Sharma et al. reported that TGF-ǃ1 mRNA expression correlates 
significantly to kidney allograft interstitial fibrosis and CAD. Angiotensin II receptor 
antagonists were shown to reduce plasma TGF-ǃ1 level by 50%, suggesting the potential of 
angiotensin II receptor antagonists to prevent CAD. Meanwhile, urine TGF-ǃ1 secretion is 
obviously higher in CAD patients than in patients with stable renal function.  
2.2 Transplantation antigen independent risk factors  
Non-immune factors and multiple risk factors jointly lead to chronic rejection-like changes 
of allograft. Rats survived for long term following homogenic renal transplantation. In case 
of renal function damage, macrophage infiltration and cytokine upregulation were observed 
in the allograft, just like chronic rejection changes following allogenic renal transplantation. 
After an allograft with functional impairment was transplanted back into the donor, early-
stage renal damage may restore normal, but late-stage damage will continue to deteriorate, 
demonstrating that early-stage chronic rejection depends on allogenic antigens and is 
reversible, while late-stage injury does not depend on allogenic antigens and is irreversible.   
1. Early-stage ischemia /reperfusion injury    
Renal allografts will undergo a series of ischemic events during organ harvesting, 
preservation, and transplantation. The longer the ischemia time, the more serious the 
reperfusion related injury. During 2- 5 d of ischemia/reperfusion injury, the expression of 
leukocyte and endothelial cell adhesion molecules, endothelin, MHC class II molecules, 
interferin Ǆ and TNF-ǂ is upregulated in kidney tissue, which is complicated by increased 
oxyradical production and T cells and macrophages in the allograft. Connolly et al. reported 
that prolonged cold ischemia affected the short-term and long-term survival of cadaveric 
renal allograft adversely, and that the benefit of HLA match for allograft survival was offset 
by prolonged cold ischemia. Ischemia /reperfusion injury damages the kidney through the 
following mechanisms: ᬅ microcirculation disturbance, early-stage renal function loss or 
delayed renal function, tubular necrosis, TGF-p increase, interstitial fibrosis; ᬆ oxyradical 
caused acute vascular endothelial cell injury and arterial sclerosis; ᬇ activation of T 
lymphocytes, causing subclinical immune reaction, arteritis, nephron reduction, 
monocyte/macrophage infiltration and interstitial fibrosis.  
2. Cytomegalovirus  
CMV infection of allograft endothelial cells will lead to chronic rejection quickly. CMV may 
enhance MHC expression, which leads to the production of anti-endothelial cell antibody 
and endothelial cell damage. In clinical practice, if acute rejection is refractory to 
immunosuppressants, and if there are a number of memory CD8+T cells in peripheral blood 
and evidence of asymptomatic CMV infection, anti-CMV treatment is usually effective to 
improve renal function. The mechanism is as follows: the immediate early gene of CMV 
encodes homologous protein, which cross-reacts to HLA-DR-ǃ chain, thus enhancing the 
recipient’s immune reaction to donor antigens. CMV encodes a glycoprotein, which is 
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homologous to the heavy chain of MHC class I antigen and can react to the light chain of 
MHC class I antigen. Active CMV infection, along with VCAM-1 expression enhancement 
and leukocyte adhesion and infiltration on capillary endothelial cells will influence allograft 
function for long term. In addition, in CMV infection, inflammatory cytokines aggavate 
endothelial cell damage and vascular pathologic changes.   
3. Drug toxicity   
Cyclosporin (CsA) and Tacrolimus (FK-506) are both CNI-type immunosuppressants. When 
they relieve early-stage acute rejection significantly, CNI induced long-term kidney toxicity 
may be an important cause for accelerating CAD progress. As a result, the long-term survival 
of allograft may decrease. Chronic nephrotoxicity of CNI is characterized by interstitial 
fibrosis, hyalinization of small artery and tubular vacuolar degeneration in the kidney. The 
causes of nephrotoxicity include kidney vasospasm, release of endothelin–ǃ, and excessive 
expression of transforming growth factor-ǃ (TGF-ǃ) and vascular endothelial growth factor 
(VEGF). It has been demonstrated recently that allograft function may be protected and 
allograft survival be prolonged by early reduction or withdrawal of CNIs and administration 
of Sirolimus (SRL) following renal transplantation, without the risk of increasing acute 
rejection (AR). In addition, the combination of nephrotoxicity-free immunosuppressants, e.g., 
SRL and Mycophenolate mofetil helps to delay the incidence of CAD.  
4. Nephron reduction    
Nephron reduction due to various causes leads to glomerular hyperfiltration, early-stage 
compensated glomerular hypertrophy and increased exudation, kidney dysmetabolism, and 
allograft failure. Nephron reduction may be associated with the following factors: ᬅ 
donor/recipient mismatch of body size, or inappropriate ratio of kidney weight /body 
weight. For instance, an allograft from a donor weighing 50kg is transplanted into a 
recipients weighing more than 90kg, which means nephron reduction and may result in 
renal functional impairment; ᬆ the donor is too young (less than three years) or too old 
(more than 60 years). If the donor is too young, the nephron is immature and cannot tolerate 
the perfusion pressure for adult kidneys. If the donor is too old, there may be vascular 
sclerosis and nephron reduction in the kidney; ᬇ sex difference. The three-year survival 
rate of allografts from female donors is 5% lower than from male donors.  
5. Hyperlipidemia  
Food rich in cholesterol and hyperlipidemia synergize in kidney injury, and they change 
macrophage function, and lead to secretion of vasoactive substances and cell proliferation, 
thus aggravating kidney damage. Controlled intake of protein can temporarily stabilize 
allograft function in patients with chronic rejection. Cholesterol-rich apoprotein B and 
triglyceride are independent risk factors for chronic rejection, and they induce arterial 
sclerosis and enhance oxidization. Oxidized low-density lipoprotein may lead to 
proliferation and migration of smooth muscle cells and aggravate vasculopathy.  
6. Other risk factors  
The following factors are shown to associate with chronic rejection: ᬅ blood pressure 
elevation is associated with allograft failure. However, which occurs first is still unclear; ᬆ 
smoking may promote allograft vasculopathy and CAD. Little investigational work has 
been done in this regard; ᬇ epidemiologic survey has revealed that continuous proteinuria 
occurs in approximately 20% of patients following transplantation, and two thirds of these 
patients suffer from CAD. Chronic allograft damage resulting from proteinuria is an 
important risk factor for CAD, possibly because of persistent protein loss, failure of 
epithelial cell repair, and epithelial atrophy and secondary tissue fibrosis.  
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3. Pathologic classification of CAD  
Allograft fibrosis and sclerosis are main pathologic changes in CAD, which can be observed 
in any anatomical structures of allograft. There may also be progressive proliferation and 
focal sclerosis of glomerular matrix, and intimal thickening of small artery and capillary in 
the kidney due to fibrosis and hyaline substance aggregation. Peritubular capillaries may 
develop multilayered basal lamina, and there may be thickening of glomerular capillary 
walls with reduplication of basement membrane and mesangial interposition. Gradual 
accumulation of interstitial matrix leads to interstitial fibrosis (IF), collagen scars, interstitial 
capillary loss and tubular atrophy (TA).   
Allograft fibrosis is the final common pathway of multi-factorial injury. Therefore, chronic 
rejection alone cannot explain the pathogenesis of fibrosis. Chronic allograft nephropathy 
(CAN) was used to describe chronic allograft fibrosis. Nevertheless, CAN is not an etiologic 
diagnosis. Thus, in 2005, the Banff consensus conference recommended adopting need-
based diagnosis and abandoning the concept of ‘CAN’. According to the Banff 2005 meeting 
report, possible causes of IF/TA include drug toxicity (especially calcineurin inhibitor 
toxicity), bacterial or viral infection, hypertension, obstruction, recurrent and de novo 
glomerular and tubulointerstitial diseases, as well as chronic rejection. Pathologic changes 
vary depending on different etiologic factors, and they should be discriminated.  
Macroscopic examination reveals no obvious allograft changes at the early-stage of CAD, 
but obvious shrinkage, thickening and adhesion of renal capsule, with scars of various sizes 
on the uneven, pale surface of kidney at the late-stage of CAD. Small scarring kidney is hard 
and has a thin cortex. Histopathologic changes include glomerular, interstitial, tubular and 
vascular changes.  
1. Transplant glomerulopathy 
Transplant glomerulopathy is mainly characterized by glomerular basement membrane 
thickening, glomerular mesenterial lysis, and accumulation of mesenterial matrix, 
mesenterial sclerosis, and glomerulosclerosis. However, it usually does not present with 
obvious proliferative reaction or dense substance deposition. In this way, it can be 
differentiated from membranoproliferative glomerulonephritis (Figure 1). Immune injury is 
generally thought to be the main cause for transplant glomerulopathy, because it correlates 
obviously to endothelial cell C4d deposition.  
  
 
Fig. 1. 
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2. Interstitial fibrosis 
Interstitial fibrosis is not specific to CAD, but is the final outcome of various kidney 
diseases. Various immune, hemodynamic and metabolic factors may lead to interstitial 
fibrosis. Tubular cell atrophy, diffuse interstitial infiltration of monocytes and lymphocytes, 
laminin and fibronectin expression increase, and gradual interstitial fibrosis may be 
observed (Figure 2). A number of proinflammatory and fibrogenic cytokines expressed in 
renal allografts may accelerate renal fibrosis, including tumor necrosis factor-ǂ, 
transforming growth factor-ǃ, platelet-derived growth factor, interferon-Ǆ, and basic 
fibroblast growth factor. These factors are usually deemed early-stage markers for fibrosis.  
  
 
Fig. 2. 
3. Tubular atrophy 
Tubular atrophy (TA) is also a non-specific manifestation of various chronic kidney injuries. 
Ischemia/reperfusion injury, drug nephrotoxicity and immune injury may lead to TA. 
Generally, tubulitis is characteristics of acute cell-mediated rejection; however, whether 
tubulitis is the sole cause for tubular atrophy is uncertain. Tubular basement membrane loss 
due to acute rejection may cause late-stage tubular atrophy. At 2-3 weeks following 
transplantation, persistent peritubular granulomatous reaction, infiltration of tubular 
basement membrane by multinucleated giant cells, and partial or complete tubular atrophy 
can be observed (Figure 3). Therefore, immune injury may be an important factor for TA.  
  
 
Fig. 3. 
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4. Transplant vasculopathy 
Transplant Atherosclerosis 
Transplant atherosclerosis may result from donor factors, non-immune injury (e.g., CNI 
nephrotoxicity) and chronic rejection. However, there are T cells or macrophages that infiltrate 
the affected vascular intima, which usually means vascular endothelitis (Figure 4). The 
incidence rate of systemic atherosclerosis increases in patients with chronic rejection, while 
renal failure per se does not influence the incidence of atherosclerosis greatly. Moreover, graft 
atherosclerosis occurs mostly in young, hypersensitive recipients or those with late-stage acute 
rejection. This suggests that transplant atherosclerosis is closely associated with immune 
injury. The specification of diagnostic criteria for chronic rejection and other entities by the 
Banff 2005 conference was an important achievement, and the positive staining for C4d in 
peritubular capillaries is thought to correlate to AMR (antibody mediated rejection).  
  
 
Fig. 4. 
Arteriolar hyalinosis 
Arteriolar hyalinosis is a characteristic feature of hypertensive nephrosclerosis, diabetic 
nephropathy, and chronic calcineurin renal toxicity. Hyaline change in the media of the 
arteriole, which may represent a consequence of myocyte necrosis, is a characteristic feature 
of cyclosporine-associated arteriolopathy (Figure 5). In many circumstances, such pathologic 
changes are not direct evidence of diagnosis, and diagnosis should be made with reference 
to previous pathologic findings obtained by biopsy.  
   
 
Fig. 5. 
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In summary, allograft fibrosis and sclerosis are caused by multiple factors, and they are the 
final manifestations of various acute and chronic kidney injuries. Interstitial fibrosis and 
tubular atrophy are non-specific. Therefore, a range of diagnostic criteria of CAD should be 
further investigated, and these diagnostic criteria can and should define specific lesions, 
thus enabling identification of pathogenic processes that affect the allograft, such as drug 
toxicity, bacterial or viral infection, hypertension, obstruction, recurrent or de novo renal 
diseases, and acute and chronic cell and/or antibody-mediated rejection.  
4. Injury mechanism for CAD  
4.1 Humoral immunity-mediated injury    
Antibodies can contribute to transplant rejection through the classical pathways, such as 
activation of complements and ADCC. After antibody binding to transplantation antigens, 
complements are activated, followed by activation of the complement-coagulation system, 
which directly leads to destruction of target cells, vasodilatation, and thrombosis, resulting 
in allograft rejection. Athough such injury is typical for hyperacute rejection, vascular 
intimal thickening and presence of complements, immunoglobin and anti-endothelial cell 
antibody in the necrotic vascular wall have been observed in allografts with chronic 
rejection. There is another pathway through which T lymphocytes recognize transplantation 
antigens, i.e., the indirect pathway. In this indirect pathway, TCR on CD4+ T cells can 
recognize donor’s MHC molecule allogenic antigen peptide treated and presented by APCs, 
also called type II helper T cell (CD4+Th2) reaction. CD4+ T cell activation by the indirect 
pathway reveals the priming of the rejection effector mechanism, which includes delayed 
hypersensitivity, cell-mediated toxicty and production of allogenic antibodies. This 
mechanism exacerbates acute rejection, and plays a major role in CAD. IL-4 and IL-10 
produced by Th2 cells are involved in humoral immunity. Activation of helper T cell surface 
antigen specific TCR triggers intracellular reaction to synthesize specific new antibodies, 
and this plays an important role in chronic rejection. Early-stage ischemia /reperfusion 
injury can also activate immunity and upregulate proinflammatory mediators to produce 
antibodies in the recipients. For instance, in ischemic tissues, vascular endothelial cell 
phenotype is activated, triggering new antigen expression and leading to immune complex 
deposition.  
4.2 Cellular immunity-mediated injury   
In transplant rejection, antigen presenting cells, e.g., dendritic cells, monocytes, and 
macrophages are crucial for triggering immune response through: ᬅ acquiring, processing 
and presentating antigens to TH/TDTH and B cells, thus activating first messengers; ᬆ 
secreting second messengers, e.g., IL-1, thus leading to TH cell activation and release of IL-2, 
IL-4, IL-5, IL-6 and IFN-γ. Under the action of these cytokines, TDTH, Tc, and B cells that 
have recognized transplantation antigens begin to proliferate and differentiate into effector 
Tc, TDTH and antibody secreting cells, leading to transplant rejection. Tc cells directly kill 
target cells, and TDTH cells contribute to rejection through inducing delayed hypersensitive 
inflammation. At early-stage acute rejection following renal transplantation, CD4+T cells 
directly recognize MHC class II antigens in the allograft, and CD8+T cells directly recognize 
MHC class I antigens in the allograft, producing strong cell- and cytokine-mediated 
reactions and clinical manifestations of acute rejection. In chronic rejection, weak reactions 
occur through CD4+Th2 (indirect presentation as mentioned above). Donor MHC may peel 
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from the parenchymal cells of allograft, enter blood circulation, and be phagocytized and 
processed by recipient’s APCs, and be presented by recipient’s MHC, or be taken up and 
processed in situ by macrophages. The recipient’s APCs interalize exogenous proteins 
derived from the allograft, and process and present polypeptides to T cells, thus providing 
essential signals for lymphocyte activation. This is the classical pathway for antigen 
processing and presentation by the immune system. In animals immunized with donor’s 
MHC class II antigens, allograft rejection is accelerated significantly, including serious 
vascular and cellular rejection, which demonstrates the role of the allogenic recognition 
based indirect pathway in transplant rejection. Nevertheless, immunosuppressants prevent 
acute rejection and induce CD4+Th2 reaction, leading to development of chronic rejection.  
The intimal plaques of allograft artery in chronic rejection comprise mainly macrophages. 
Macrophages upregulate the expression of fibrosis factors, interleukin-1(IL-1), IL-6, TNF-a 
and membrane cofactor protein -1(MCP-1) and growth factors, particularly, fibroblast 
growth factors (bFGF) and transforming growth factors around glomeruli and vessels, thus 
promoting vascular wall hypertrophy, glomerulosclerosis and kidney fibrosis. Platelet 
derived growth factors (PDGF), intracellular adhesion molecule (ICAM) and vascular 
adhesion molecule -1(VCAM-1) are also present on glomerular capillary endothelial cells 
and other structures. Upregulation of lymphocytes function associated antigen -1(LFA-1) 
and very late appearing antigen -4(VLA-4), as well as infiltrating cells and cytokines in the 
allograft promote the waterfall effect of adhesion molecules.  
In triggering immune reactions, multiple cytokines such as TNF and IFN-Ǆ promote 
lymphocytes to mature and helper T cells Th1 to synthesize IL-2, IFN-Ǆ and IL-12. Anti-
inflammatory cytokines, e.g., TGF-ǃ, lead Th2 cytokines IL-4 and IL-10 to mature, and 
suppress immune reactions against allogenic antigens. During rejection, all these cytokines 
are present in the allograft. However, in case of immune tolerance, Th1 cytokines reduce, 
and Th2 cytokines increase. CD4+Th2 cytokines, particularly, IL-4, IL-10 and TGF-ǃ, 
suppress the synthesis of matrix metalloproteinases (MMPs) on smooth muscle and 
macrophages. MMPs regulate cellular matrix deposition and degradation. Hence, MMPs 
suppression causes vascular endothelial cell matrix to accumulate, gradually resulting in 
arterial sclerosis.  
Although CD4+Th2 reactions dominate in chronic rejection, other cells, including 
endothelial cells, CD8+ T cells, NK cells and macrophages, are required to maintain chronic 
rejection. For instance, CD8+T cells can activate allogenic class I antigens crosslinking on 
endothelial cells to produce IL-4, IL-10 and TGF-ǃ. Crosslinking of allogenic antibodies to 
class I antigen molecules on endothelial cell surface will lead to activation and synthesis of 
TGF-ǃ, PDGF and FGF.  
4.3 Allograft structural component reactivity  
Various structural components of allograft exhibit different reactivity at early-stage and late-
stage following transplantation. In chronic rejection, vascular obstruction results from 
repeated activation, injury, proliferation and repair of endothelial cells and deposition of 
extracellular matrix proteins. Vascular wall injury is caused by homogeneous immune 
reactions because early-stage antigens or proinflammatory factors (e.g., leukotriene, 
oxyradicals) upregulate complements and adhesion molecules. Allograft arteriosclerosis is 
associated with autoimmune reactions induced by heat shock protein produced by activated 
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endothelial cells. Changes in the phenotype of activated endothelial cells cause cell 
denudation and exposure of subendothelial collagen to platelets and plasma proteins, which 
promotes focal coagulation and thrombosis. Ischemic tissues produce various coagulants, 
and injured or activated endothelial cells release cytokines, chemical inducers, mediators, 
thromboxanes, leukotriene and growth factors, including PDGF, platelet-activating factor, 
NOSi and elastin. Chemical inducers and adhesion molecules promote circulating 
leukocytes to migrate to the site of injury, and then to vascular wall and perivascular space. 
Inflammatory reactions caused by cytokines and growth factors result in vascular smooth 
muscle proliferation and migration, tissue deformation, and vascular involvement. In 
chronic rejection, there are focal or diffuse glomerular changes, and macrophage infiltration 
may accelerate early-stage glomerular injury to develop into glomerulosclerosis. 
Glomerulosclerosis and vascular luminal narrowing lead to gradual renal functional 
impairment and systemic hypertension. As a result, remnant nephrons are subject to 
glomerular hyperfiltration and fibrosis, and finally lose function. Non-specific interstitial 
fibrosis and tubular atrophy stem from organ injury. Therefore, in the presence of early-
stage injury following organ transplantation, despite persistent administration of 
immunosuppressants, renal function may be impaired gradually over several months to 
several years, and these changes correlate to the reactivity of various structural components 
of allograft.  
4.4 Recurrent and de novo allograft disease  
Recurrent glomerulonephritis posttransplantation refers to glomerulonephritis of allograft 
following renal transplantation, which is pathologically identical to glomerulonephritis of 
autologous kidney. De novo glomerulonephritis posttransplantation refers to 
glomerulonephritis of allograft following renal transplantation, which is pathologically 
different from glomerulonephritis of autologous kidney or the pathology of allograft prior 
to transplantation. The key to diagnose recurrent and de novo glomerulonephritis lies in the 
availability of biopsy findings of the autologous kidney and allograft prior to 
transplantation. In effect, glomerulonephritis is virtually recurrent in all cases. The incidence 
of recurrent nephropathy of allograft correlates obviously to the histologic type of kidney 
before transplantation and the time following transplantation. Some glomerular diseases are 
likely to recur, e.g., mesenterial capillary nephritis, and IgA nephropathy, with the incidence 
rate of 50-90%. However, these recurrent diseases are unnecessarily influence allograft 
function seriously. Generally, renal function impairment progresses slowly, with long stable 
periods. Tables 1-2 list common recurrent and de novo allograft diseases. Currently, most 
investigations focus on the incidence rate, risk factors and clinical manifestations of 
recurrent allograft nephritis. Clinically, large doses of immunosuppressants are 
administered to prevent allograft rejection, but allografts may develop recurrent nephritis, 
demonstrating that currently available immunosuppressants cannot suppress the incidence 
of preexisting glomerular diseases. Novel immunosuppressants e.g., MMF and Rapamycin, 
can suppress cell proliferation in vitro, but their efficacy for recurrent glomerular disease 
has not been established. Therefore, further investigating the treatment of recurrent and de 
novo nephritis will deepen the understanding of the pathophysiology of autologous 
glomerulonephritis and immune pathogenesis of allograft rejection.  
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Pathologic classification  Recurrent rate (%) Allograft loss rate (%) 
FSGS 20~40 25 
IgA nephropathy  50 5~10 
Membranous nephropathy  20 5~10 
MPGN-I 25 5~10 
MPGN-II 90 20 
HUS 10~50 10~50 
HSPN 30~80 10 
Wegener’s granuloma 5~20 5~20 
Anti-GBM disease  <10 <1 
Lupus nephritis  5~10 <5 
FSGS: focal segmental glomerulosclerosis, MPGN: membranoproliferative nephritis, HUS: hemolytic 
uremic syndrome, HSPN: anaphylactoid purpura nephritis  
Table 1. Recurrent rate and allograft loss rate of allograft nephritis 
 
Pathologic classification Incidence rate (%)  
Etiologies 
Allograft nephropathy  5 Rejection? T cell mediated endothelial cell injury?  viral infection?  
De novo membranous nephropathy  2 Rejection related? de novo antigens produced after 
allograft injury form immune complexes in situ 
De novo HUS 1~3 Calcium channel blockers, allograft ischemia, transplant rejection  
De novo MPGN ? 2 HCV, cryoglobulin? deposition of HCV antigens in glomeruli 
Alport syndrome 
Anti-GBM disease  Rare IgG product related to type IV collagen ǂ chain 
Table 2. Common de novo allograft diseases 
4.5 Posttransplantation lymphoproliferative disease   
PTLD is one of the serious complications after organ and marrow transplantation, which 
presents with lymphocyte proliferation disorder and formation of lymphoma. The 
probability of PTLD in renal transplantation patients is 20 times that in normal populations. 
Nevertheless, the incidence rate of PTLD is relatively low (1 %-10%) in renal transplantation 
patients. PTLD usually affects lymph nodes, the allograft, small intestine and central 
nervous system, and it occurs mostly in the 2 years following transplantation. PTLD 
localized to the allograft usually occurs earlier than that outside the allograft. PTLD occurs 
earlier in patients positive for EB virus than in those negative for EB virus. PTLD mostly 
stems from B lymphocytes (approximately 87%), and sometimes from T lymphocytes (12%). 
PTLD stemming from B lymphocytes is mostly complicated by EB virus positivity, while 
only 38% of PTLD stemming from T lymphocytes is complicated by EB virus positivity. 
Although PTLD may originate from the donor’s cells or the recipient’s cells, it mainly 
originates from the donor’s cells. PTLD originating from the donor’s cells has a better 
prognosis than that originating from the recipient’s cells. PTLD has varied clinical 
manifestations, which relate mainly to the affected site and severity of pathologic changes. 
Common clinical manifestations include ardent fever, neutrocytopenia, anemia, anorexia, 
diarrhea, and stomachache. Imaging examinations are not specific for the diagnosis of 
www.intechopen.com
 After the Kidney Transplant – The Patients and Their Allograft 
 
346 
PTLD. A definite diagnosis depends on pathologic examination. When PTLD is localized to 
the allograft, with diffuse infiltration, but without obvious masses, it resembles allograft 
rejection with gradual function loss.  
5. Diagnosis of CAD  
5.1 Clinical manifestations  
Chronic allograft rejection mostly occurs at 2 months to several years following 
transplantation, with clinical manifestations such as progressive impairment of allograft 
function, proteinuria and /or anuria, slow increase in blood creatinine (clinically termed 
“climbing creatinine”), hypertension, progressive anemia and allograft shrinkage.  
5.2 Imaging examinations  
1. Color Doppler ultrasonography  
Since the allograft is shallow, ultrasonic imaging of the allograft will not be influenced 
substantially by organs and muscle tissue. In addition, due to great acoustic impedance 
difference between the kidney and surrounding tissues, allograft structures, kidney vessels, 
ureters and adjacent tissues are shown distinctly. Ultrasonography is able to reveal the 
allograft size, kidney structures, and various complications of renal transplantation. With 
the use of color Doppler flow imaging (CDFI) and color Doppler energy (CDE) techniques, 
blood flow and blood supply to the allograft, and vascular complications following 
transplantation can be shown clearly. In addition, under ultrasonic guide, biopsy, 
puncturation and drainage, and visualization are accurate, simple, safe, and non-
radioactive, and unlikely to cause complications. Hence, ultrasonography is the preferred 
imaging modality for allograft. Under ultrasonography, CAD exhibits the following 
manifestations: the allograft size increases first and then decreases gradually, with a long 
diameter usually less than 9cm; the kidney parenchyma has enhanced and thickened echoes; 
the cortex becomes thinner, with indistinct borderline between the kidney parenchyma and 
renal sinus; at late-stage, the kidney structure is deranged. CDFI frequency spectrum 
indicates reduced vessels. At late-stage in serious cases, in absence of blood flow in 
interlobar and arcuate arteries, acute rejection cannot be excluded by ultrasonography. The 
renal vascular systolic peak flow rate decreases, and the end-diastolic flow rate also 
decreases. The renal vascular resistance differs significantly between various orders of 
vessels, particularly between the renal artery and arculate artery. However, the renal 
vascular resistance is lower than that in hyperacute rejection, accelerated rejection, and acute 
rejection, but higher than normal. Interstitial vascular resistance is thought to be small; 
hence, it may be insensitive to Doppler ultrasonography. In contrast, vascular resistance is 
obvious; hence, it may be sensitive to Doppler ultrasonography. If the RI is normal or less 
than0.7, CAD cannot be ruled out by ultrasonography. CDE indicates decreased renal 
vascular perfusion, particularly, in the cortex.  
2. Radionuclide imaging 
In CAD, the allograft is diminished, and its perfusion and excretion, particularly, uptake, are 
impaired. Isotope nephrogram indicates perfusion reduction.  
3. Digital subtraction angiography (DSA)  
In CAD, kidney arteries reduce, and they are thin and bead-like. The kidney parenchyma 
presents with nonuniform density and patchy changes.  
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4. CT and MRI 
CT and MRI are atraumatic, and have high resolution for soft tissues; hence, they are 
complementary to other imaging methods for allograft.  
5.3 Pathologic study 
Currently, biopsy is the most direct, reliable tool for rejection diagnosis. In clinical practice, 
biopsy findings should be considered in combination with various clinical manifestations 
and other immunologic, biochemical and imaging findings. Percutaneous thick needle 
aspiration biopsy or fine needle aspiration biopsy (FNAB) are frequently adopted. If they 
fail to establish a diagnosis, open biopsy may be considered.  
1. Fine needle aspiration biopsy (FNAB)  
This method is safe, fast, highly sensitive and specific, and allows continuous observation. 
Under the guide by ultrasonography or palpation, a 0.7-0.8mm needle with core is inserted 
into the cortex of the shallower kidney pole, and 10-15tB kidney parenchyma is aspirated 
and mixed with 5ml heparinized RPMl 1640. The cells are harvested by centrifugation and 
smeared onto slides. May-Grunlvcald-Giemsa or Wright staining is performed, and cells are 
counted under an immersion objective. Meanwhile, blood is sampled from the fingers and 
cells are counted as described above. In typical specimens, there are at least 7 kidney 
parenchymal cells (endothelial cells, basophilic small tubular epithelial cells, large 
transparent tubular epithelial cells, large granular tubular epithelial cells or glomerular 
mesenterial cells) out of 100 inflammatory cells, or there is at least 0.25 parenchymal cell per 
high power field. The number of a kind of inflammatory cells in the peripheral blood is 
subtracted from the number of the same kind of inflammatory cells in the allograft to obtain 
the increament (I). The negative values are discarded. Then, the I values that represent 
various types of inflammatory cells multiply with a correction coefficient that reflects the 
contribution of the inflammatory cell type to obtain the corrected I (CI). The CI for each type 
of inflammatory cells is cumulated to get the total CI (TCI), which represents the extent of 
inflammatory reactions. Meanwhile, kidney parenchymal cells are graded according to their 
morphology: 0, morphologically normal; 1, swelling; 2, swelling and vacuolar degeneration; 
3, swelling, vacuolization and presence of inclusion materials; 4, necrosis. FNAB specimens 
can also be investigated by immunocytochemical staining, e.g., peroxide-anti-peroxydase 
(PAP) staining, indirect immunofluorescence staining, double immunofluorescence staining, 
immunogold or immunosilver staining, and biotin-avidin immunostaining. FNAB is 
accurate for diagnosing acute cell-mediated rejection, but is useless for diagnosing CAD and 
vascular rejection.  
2. Percutaneous thick needle aspiration biopsy 
This method is the most determinant and reliable tool for differentiating allograft rejection, 
cyclosporin A toxicity or acute tubular necrosis. In China, the most frequently used needles 
are Menghini, Franklin-Vim-Silverman, Tru-Cut and Jamshidi types, which are all fit for 
allograft puncturation. Specimens can be aspirated from the outer edge of the midpoint of 
the upper and lower kidney poles or the upper kidney pole. For shallow allografts, the 
needle can be inserted under the guide of palpation. However, in obese patients, 
ultrasonography or fluoroscopy (with or without intravenous pyelography) may be adopted 
to guide needle insertion. In case that all these methods failed, CT guide may be considered. 
The complications are mainly hematuria, perirenal hematoma, arteriovenous fistula, 
lymphatic fistula and infection.  
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3. Pathologic diagnosis  
a. The allograft is slightly enlarged or normal at early-stage, and is diminished 
obviously at late stage. At late stage, the allograft is light and pale, with uneven 
surface and scars; hence, it is called “small scarring kidney”. The renal capsule is 
obviously thickened and adhered, and cortex atrophy can be observed on the cross-
section. Renal function deteriorates progressively, which is proportional to the 
degree of interstitial fibrosis and glomerulotubular atrophy.  
b. Histologic changes include intimal proliferation dominated proliferating vasculitis, 
capillary basement membrane thickening and mesenterial matrix increase. There 
are several pathologic types.  
1. Occlusive vasculitis  Small artery and arteriole are affected seriously, and interlobar and 
arcuate arteries may also be affected. In small interlobar artery, afferent glomerular artery 
and larger artery, smooth muscle and fibroblast proliferation and fibrosis of intima, intima 
thickening, and luminal narrowing and even obstruction can be observed. Proliferating cells 
are mostly intimal fibroblasts, and smooth muscle cells originate from the intima. Both cell 
types produce collagen fibers ultimately. In some cases, subendothelial smooth muscle cells 
proliferate obviously around the lumen axis, and take on a cyclic, onion-like shape, forming 
so-called “second tunica media”. Serious arterial lesions may influence blood supply to the 
kidney, lead to multiple infarction, ischemic renal parenchymal atrophy, and renal 
interstitial sclerosis.  
2. Renal interstitial sclerosis   Diffuse or focal renal interstitial fibrous proliferation is the 
major change, which involves the cortex to the medulla. Renal interstitial matrix 
proliferates, with rare cells and infiltration by lymphocytes and monocytes. Tubular changes 
are varied, including basement membrane thickening and tubular epithelial cell 
regeneration. Regenerated tubular epithelial cells are large and may have multiple nuclei. 
Occasionally, there are single or groups of necrotic epithelial cells. Some tubules are dilated 
in compensation, resembling mesenchyme. Rejection glomerulonephritis or recurrent 
glomerulonephritis may be observed. Some patients present with obvious proliferative 
glomerulonephritis, with obvious increase of glomerular matrix or crescent formation.  
c. Immunofluorescence assay: IgG, IgM and C3 deposit on the glomerular capillary 
wall and interstitial vascular wall. In particular, in occlusive vasculitis, infiltrating 
inflammatory cells contain strong fluorescence-emitting IgM.  
d. Electron microscopy: The space between endothelial cells and basement membrane 
is widened obviously in capillary loop and electron dense substance deposits in a 
linear or granular manner, with obvious basement membrane thickening. There is a 
lot of linear and granular electron dense substance deposition along the tubular 
basement membrane. Mesenterial matrix and surrounding basement membrane are 
thickened obviously, and are curved. Collagen increases in small artery wall, and 
smooth muscle cells and fibroblasts proliferate. Lipid droplets increase and 
myofilaments decrease in the cytoplasm of smooth muscle cells, which may 
become fibroblasts or foam cells.  
e. Oligonucleotide microarray hybridization assay: B cell chemokine (CXCL13) and 
mast cells may be determined as predictors for CAD.  
4. Differential diagnosis    
CAD presents with glomerulosclerosis, recurrent or rejection related glomerulonephritis. 
Recurrent glomerulonephritis refers recurrence of preexisting nephritis in the allograft, 
which can be recognized through examining the recipient’s original kidney specimens. 
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Rejection related glomerulonephritis and focal glomerulonephritis can be differentiated by 
vasculopathy. In serious rejection-related glomerulonephritis, glomerular capillary 
basement membrane is thickened obviously, which should be differentiated from 
membranous glomerulonephritis through PAS or PASM staining. In rejection-related 
glomerulonephritis, there are no spike-like deposits on the epithelial surface of basement 
membrane, but bilayer basement membrane. In CAD, vascular sclerosis of the allograft 
should be differentiated from atherosclerosis. Vascular sclerosis is characterized by typical 
concentric proliferation of smooth muscle and breach of internal elastic layer, but no 
cholesterol crystals. In contrast, atherosclerosis is characterized by deranged intimal fibers 
and obvious cholesterol crystals. In CAD, interstitial sclerosis is obvious sometimes, which 
should be differentiated from chronic interstitial nephritis. In CAD, there are renal 
interstitial sclerosis, rare nuclei, spare fibers, and few inflammatory cells; hence, the tissue 
resembles mesenchyme. In chronic interstitial nephritis, fibers are usually dense in scar 
tissues, with abundant nuclei and a certain number of inflammatory cells.  
6. Prevention and treatment of CAD  
CAD treatment  
No effective treatments for CAD are available yet. The main therapeutic options include 
controlling blood pressure, administering immunosuppressants, stosstherapy with 
Methyllprednisolone (MP), intermittent intravenous infusion of Cyclophosphamide (CTX), 
and use of antithymocyte globulin (ATG), antilymphocyte globulin (ALG), OKT3 and OKT4 
monoclonal antibodies, tripterygium glycosides,  Bailing capsule, and Niaoduqing granules. 
The overall therapeutic effect is not good. Over recent years, many treatments have been 
reported. However, the overall strategy involves the rational use of immunosuppressants, 
preventing and treating risk factors, and prolonging the functioning life of remnant 
nephrons. Below are some treatments that are effective for CAD:  
1. Dietary therapy   Dietary therapy is one of the fundamental measures to delay renal 
failure in CAD. It has been established both clinically and experimentally that low 
protein diet and essential amino acid therapy can delay chronic renal failure in most 
patients. Dietary therapy is mainly aimed to minimize metabolic waste, while 
providing nutrients to meet basic physiologic needs. By correcting dysmetabolism of 
nutrients, dietary therapy can relieve the burden on remnant nephrons, correct 
hemodynamic disturbances, and delay the progress of kidney disease. The measures 
include ᬅ low protein diet: It is generally thought that low protein diet should be 
prescribed for patients with chronic renal failure once the endogenous creatinine 
clearance rate (Ccr) falls to 55ml/min. Meanwhile, sufficient energy should be supplied. 
This is because high protein diet will increase kidney blood flow and the glomerular 
filtration rate drastically. Long-term high protein diet will result in persistent high 
glomerular filtration and glomerulosclerosis through cumulative effect. ᬆ essential 
amino acids (EAAs): It has been demonstrated that EAAs can improve the nutritional 
status of patients with chronic renal failure, and can reduce the adverse effect of 
proteins and common amino acids on the hemodynamics of kidney, thus effectively 
delaying renal functional impairment. Generally EAAs should be given at week 2 of 
low protein diet. ⑨ low phosphorus diet and calcium supplementation: Strict  
control of dietary phosphorus will prevent hyperphosphatemia and secondary 
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hyperparathyroidism, and relieve tubular interstitial damage. Calcium supplementation 
should be considered for patients with hypocalcemia and controlled hyperphosphatemia. ᬈ Supplementation of vitamins and trace elements: Proper supplementatin of water 
soluble vitamins and trace elements may benefit CAD patients.  
2. Cyclosporin A (CsA)  The efficacy for CsA is still controversial. According to a 
retrospective study following up 435 cases for 14 years in the United States, the median 
allograft survival rate is 3 years. Compared to Azathioprine, CsA showed non-
inferiority in relieving renal functional impairment. The median allograft survival rate 
was 11.6 years in CsA treated patients, and was 9.7 years in Aza treated patients. In 
animal models, CsA cannot prevent the emergence of pathologic characteristics of CAD 
after heart, kidney or aorta transplantation. It was also demonstrated that the use of 
CsA can increase the early-stage success rate obviously and the long-term survival rate 
as well. Long-term use of CsA is especially superior to Aza. Nevertheless, CsA may 
increase angiotensin and TGF-ǃ, which is not desirable for CAD treatment. A few 
scholars hold that low doses of cyclosporin A (CsA) in combination with other 
immunosuppressants e.g., Mycophenolate mofetil (MMF), is somewhat effective for 
CAD.  
3. FK506  Ji et al. reported that FK506 may delay the progress of CAD safely and 
effectively. Wang et al. reported that FK506, in place of CsA, was effective for early-
stage CAD, particularly, in cases with Scr less than 400umo/L. After FK506 treatment, 
the Scr level decreased substantially, and hypertension and renal dysfunction improved 
obviously. One-year follow-up indicated that the patients’ condition was stable. 
Nevertheless, FK506 treatment is less effective in cases with Scr more than 400umol/L. 
Hence, it is concluded that FK506, in place of CsA is effective for early-stage CAD. 
Theruvath et al. reported that the FK506+MMF immunosuppressant regimen can 
reduce anti-donor HLA antibody in recipients, which is of significance to prevent and 
treat CAD. A US-based, multi-center study primarily on renal transplantation showed 
that in comparison with CsA, FK506 can effectively prevent acute or 
glucocorticosteroids or antibody resistant allograft rejection, with increasing side 
effects. Among 77 patients with acute rejection, 74% of them healed after the combined 
use of CsA and FK506. 20 patients had obvious vasculopathy, which was refractory to 
antibody treatment. However, whether FK506 stabilizes allograft function for long is 
still unclear.  
4. Mycophenolate mofetil (MMF) MMF is superior to azathioprine in the treatment of 
CAD. It was reported that three large clinical trials were undergoing to investigate the 
efficacy of MMF plus CsA plus prednisone. The dose of MMF to prevent acute rejection 
is 2g/d or 3g/d. Compared to the control group or the Aza treatment group, the 
incidence rate of acute rejection decreased obviously at 6 months postoperatively, as 
confirmed by biopsy. The dose of 3g/d was more effective than 2g/d. MMF may lead 
to abdominal discomfort, leukopenia and infection. It is now thought that MMF can 
reduce the incidence of acute rejection and irreversible CAD. MMF in combination with 
low doses of cyclosporin A (CsA) and prednisone decreased blood creatinine, cured 
proteinuria and improved renal function in patients with CAD. MMF was found to 
ameliorate CAD caused chronic renal dysfunction, particularly, mild to moderate renal 
dysfunction that develops in the first three years after renal transplantation. 
Nevertheless, long-term follow-ups should be carried out. With the use of MMF, the 
dose of CsA and glucocorticosteroids can be decreased to reduce the toxic or side effects 
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of CsA and glucocorticosteroids. The toxic or side effects of MMF are acceptable. With 
accumulating experience with the clinical use of MMF, the incidence rate of MMF’s 
adverse reactions may be further decreased. CAD patients may benefit from the 
replacement of Azathioprine with MMF.  
5. Sirolimus Sirolimus is a macrolide antibiotic produced by Streptomyces (an 
actinomycete). As an immunosuppressant, it resembles FK506 structurally. It is not 
nephrotoxic, and can reduce chronic CsA toxicity. Sirolimus suppresses vascular 
proliferation, and fibroblast proliferation in vitro; hence, it may prevent CAD. Sirolimus 
prevents allogenic CAD also through downregulation of adhesion molecule and growth 
factor encoding gene expression. Replacing calcineurin inhibitors with Sirolimus may 
delay the incidence of CAD and relieve its clinical symptoms.  
6. Lelfunomide  In rodent models of heart transplantation with chronic vascular rejection, 
Lelfunomide exhibited very significant efficacy, and it can reduce and reverse chronic 
vasculopathy in the allograft. Unlike other immunosuppressants, Lelfunomide will not 
induce diabetes. Lelfunomide has not been approved for clinical use, but it may become 
a new treatment for CAD.  
7. Polyunsaturated fatty acids   Experimental and clinical studies have demonstrated that 
fish oil treatment can regulate immune reaction. In rat models of heart transplantation, 
ω-3 polyunsaturated fatty acid can prolong the survival time of allograft obviously. 
However, allograft survival prolongation correlated to and the reduction of the ω-3 
fatty acid content. It is possible that the ratio of dietary ω-3/ω-6 fatty acids is more 
important than the level of certain fatty acids. ω-3 polyunsaturated fatty acids may 
regulate immunity via multiple mechanisms: to suppress the effects of IL-1/TNF, to 
change DR antigen expression, and to reduce vascular smooth muscle cell proliferation 
and vascular permeability. Another study demonstrated that ω-3 polyunsaturated fatty 
acids (e.g., fish oil) in combination with 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) 
reductase inhibitors can reduce the incidence rate of allograft rejection, and they have 
no obvious toxic and adverse effects.  
8. Hypolipidemic treatment  HMG-CoA reductase inhibitors (e.g., Statins) are commonly 
used hypolipidemic agents. Regardless of the blood lipid level in patients, these drugs 
exhibit good protective effect. In addition to decreasing cholesterol, these drugs can 
stimulate vascular endothelial cells to release monoxide nitrogen, restore endothelial 
cell function, and improve kidney hemodynamics. They can also suppress platelet 
aggregation and thrombosis. It was reported that Simvastatin can reduce the incidence 
rate of coronary heart disease in rat models for heart transplantation, possibly through 
reducing the production of 7FXAz. Statins reduce the incidence rate of CAD indirectly, 
through protecting allograft vessels. CsA, glucocorticosteroids and rapamycin can lead 
to blood lipid increase. However, it is still unclear to what extent blood lipid should be 
increased for long. Large multicenter randomized controlled trials or systematic 
appraisals should be carried out to address this issue.  
9. Control of hypertension   It has been demonstrated that 90% of CAD patients present 
with various degrees of hypertension, and require antihypertensive treatment. 
Hypertension leads to CAD, possibly through increasing renal vascular shear stress, 
leading to vascular sclerosis, increasing renal vascular resistance, and finally leading to 
renal ischemia. CAD treatments include control of hypertension and hyperlipidemia. 
Angiotensin converting enzyme inhibitors or angiotensin receptor blockers can change 
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intraglomerular pressure and slow down renal functional impairment. Angiotensin 
suppression can relieve vascular fibrosis and injury in CAD.  
10. Anticoagulant therapy  As most patients with chronic renal failure have disturbances of 
blood coagulation, anticoagulant therapy can delay the progress of kidney disease. It 
has been demonstrated recently [39] that low molecule weight heparin can effectively 
improve the functional and morphologic status of CAD; however, the precise 
mechanism is to be elucidated. In addition, traditional Chinese medicines that can 
promote blood flow and remove blood stasis, e.g., Danshen and Szechwan Lovage 
Rhizome, exhibit certain therapeutic effects on CAD. However, these therapies need 
further experimental investigation and clinical observation.  
11. Hyperbaric oxygen treatment   Pang et al. demonstrated in animals that hyperbaric 
oxygen is important to prevent or relieve CAD. It was found that proteinuria was 
milder and the creatinine clearance rate was higher in the hyperbaric oxygen treatment 
group than the control group. Renal interstitial fibrosis, glomerulosclerosis, artery 
intimal thickening and T cell, monocyte/macrophage infiltration were milder in the 
hyperbaric oxygen treatment group than the control group. Therefore, it is concluded 
that hyperbaric oxygen is useful for CAD treatment. However, further clinical trials 
should be carried out in larger sample sizes.  
12. Traditional Chinese medicines  Glucosidorum Tripterygll Totorum and Bailing capsules 
are effective for CAD, and they help protect remnant nephrons and improve renal 
function in CAD. However, their mechanisms of action remain unclear. Further studies 
should be carried out to determine the pharmacokinetics, optimal medication regimen 
and dosage of traditional Chinese medicines.  
13. Excision of renal allograft  When CAD develops to renal failure and uremia, the patient 
needs dialysis to sustain life. The renal allograft is excised prior to discontinuation of 
immunosuppressants, so as to avoid the production of antibody in allograft and allow a 
second renal transplantation.  
14. Gene therapy   It may be one of the important directions in the management of CAD.  
In summary, CAD should be treated comprehensively and individually.  
CAD prevention  
1. To optimize allograft quality   Damage should be avoided during harvesting, 
preserving and trimming allografts. It has been demonstrated that the older the donor 
is, the earlier and more serious allograft glomerulosclerosis and renal interstitial fibrosis 
occur. Therefore, allografts should better be harvested from young donors.  
2. Preoperative HLA match  CAD is mainly caused by immunologic injury. Preoperative 
HLA match is critical to reduce CAD. It is currently thought that the UNOS six-antigen 
matching program is a useful tool to achieve optimal HLA match. Allografts with 
perfect match on the HI, A-A, B and DR loci should better be chosen.  
3. To reduce ischemia /reperfusion injury  The cold ischemia time should better be less 
than 20h. High quality vascular anastomosis and avoidance of vascular restenosis are 
important to reduce ischemia /reperfusion injury. In cadaveric renal transplantation, 
the use of 200mg recombinant human-superoxide dismutase (RH-SOD) can suppress 
radical-induced injury, allograft immunity, and MHCII antigen and adhesion molecule 
upregulation, thus relieving acute and chronic rejection.  
4. To reduce acute rejection   The severity, frequency and time of onset of acute rejection 
correlate closely to CAD, and acute rejection is the major immune factor for CAD. 
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Immunosuppressants have certain toxicity to allografts. Therefore, acute rejection 
should be prevented with most effective immunosuppressants at the smallest possible 
dose.  
5. To improve the patient’s compliance  Poor compliance is found to be an important 
factor for allograft failure. Hence, the patient’s compliance should be improved by 
minimizing the drug dose, educating the patient about the unwanted outcomes of 
irregular medication, helping the patient to schedule the medication, and establishing a 
close relationship with the patient.  
6. To closely monitor renal function To monitor renal function closely can help physicians 
to supervise patients taking immunosuppressants, and to find acute rejection promptly. 
Both patients and physicians must bear in mind that CAD following transplantation 
seldom has symptoms and physical signs. Therefore, regular monitoring of blood 
creatinine is feasible for monitoring long-term CAD.  
7. To perform biopsy regularly It has been demonstrated that low-grade tubulitis or 
critical acute rejection can increase the risk for CAD. If biopsy was performed regularly 
in the first several months following transplantation and rejection was detected and 
managed promptly, the creatinine level remained low in the first two years. In contrast, 
in the control group without receiving regular biopsy, the creatinine level was found 
high upon biopsy and treatment. Therefore, it is concluded that it is crucial to caution 
against acute and chronic rejection and prescribe kidney biopsy for more patients.  
8. To manage hyperlipidemia  Hyperlipidemia can promote arteriosclerosis and damage 
renal function. Pravastatin decreases lowly oxidized low density lipoprotein-cholesterol 
and triglyceride, and suppress growth factor expression and vascular smooth muscle 
proliferation. Therefore, to manage hyperlipidemia proactively may exert certain effect 
on renal arteriosclerosis.  
9. To treat hypertension Cardiovascular complications are the second leading cause for 
death one year after renal transplantation. Both CsA and FK506 can cause hypertension. 
If the systolic pressure exceeds 150mmg, autoregulation of afferent glomerular artery 
fails, and the glomerular artery dilates, which results in the production of angiotensin-2 
peptide and TGF-ǃ. TGF-ǃ promotes renin secretion. Various factors may reduce 
nephrons of the allograft, and remnant nephrons are subject to high perfusion pressure, 
high filtration and high secretion, thus causing glomerulosclerosis. At the early-stage of 
CAD, if the systolic pressure is controlled below 140mmHg, and the urine protein at 
0.25-1g/d, the renal function may not deteriorate for three years. If the urine protein is 
kept at 1-3g/d, blood pressure may be controlled with higher doses of drugs or more 
drugs. If the urine protein exceeds 3g/d, blood pressure must be controlled strictly to 
prevent renal functional deterioration for long. In addition to antihypertensive action, 
Carvedil suppresses smooth muscle proliferation.  
10. To prevent cytomegalovirus infection  The CMV infection rate is 70% -100% in the 
population. Following cadaveric renal transplantation, 8% patients develops 
symptomatic CMV disease, and the mortality rate is 20%. When CMV disease leads to 
interstitial pneumonia which requires machine ventilation, the mortality rate is 90%. In 
the CMV infection group, the three-year allograft survival rate reduced by 30%. Active 
CMV replication can be detected by CMV antigen assay, LSAB assay, and monoclonal 
antibody determination of CMV encoded PP65 antige as early as 1-6 days prior to onset 
of CMV disease. CMV disease can be prevented and treated with Ganciclovir in the first 
three postoperative months in patients positive for CMV infection.  
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